


REMARKS

The specification has been amended to insert deposit information for the specifically identified hybridoma cells. The amendment was made to comply with the requirements for biological deposits and, therefore addresses a formality. Submitted herewith is an executed statement under 37 C.F.R. §1.804(b) that the deposited biological material is a biological material specifically identified in the application as filed. Accordingly, no new matter has been added and entry thereof is respectfully requested.

Please charge any fees associated with the submission of this paper to Deposit Account Number 033975. The Commissioner for Patents is also authorized to credit any over payments to the above-referenced Deposit Account.

Respectfully submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP



ROBERT M. BEDGOOD
Reg. No. 43488
Tel. No. 858.509.4065
Fax No. 858 509.4010

Date: April 21, 2008
12255 El Camino Real, Suite 300
San Diego, CA 92130-4088
(619) 234-5000

CERTIFICATION UNDER 37 C.F.R. §§ 1.8 and/or 1.10*

(When using Express Mail, the Express Mail label number is *mandatory*; Express Mail certification is *optional*.)

I hereby certify that, on the date shown below, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: _____

Signature

(type or print name of person certifying)

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Attorney Docket: 043043-0359294

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of: PHILIP
VOLLMERS

Confirmation Number: 3217

Application No.: 10/578,856

Group Art Unit: 1614

Filed: May 11, 2006

Examiner: TBA

Title: HUMAN MONOCLONAL ANTIBODY HAVING FAT-REDUCING EFFECT

STATEMENT UNDER 37 C.F.R. §1.804(b)

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Frank Hensel, hereby state that the biological material which is deposited is a biological material specifically identified in the application as filed.

Dated: 18 April 2007

Frank Hensel
Frank Hensel